Nagamine J, Nagata R, Seki H, Nomura-Akimaru N, Ueki Y, Kumagai K, Taiji M, Noguchi H
Sumitomo Pharmaceuticals Co. Ltd, Discovery Research Laboratories II, 1-98 Kasugade Naka 3-chome, Konohana-ku, Osaka 554-0022, Japan.
J Endocrinol. 2001 Dec;171(3):481-9. doi: 10.1677/joe.0.1710481.
SM-130686, an oxindole derivative, is a novel orally active GH secretagogue (GHS) which is structurally distinct from previously reported GHSs such as MK-677, NN703 and hexarelin. SM-130686 stimulates GH release from cultured rat pituitary cells in a dose-dependent manner. Half-maximum stimulation was observed at a concentration of 6.3+/-3.4 nM. SM-130686-induced GH release was inhibited by a GHS antagonist, but not by a GH-releasing hormone antagonist. SM-130686 dose-dependently inhibited the binding of radiolabeled ligand, (35)S-MK-677, to human GHS receptor 1a (IC(50)=1.2 nM). This indicates that SM-130686 stimulates GH release through the GHS receptor. The effect of a single oral administration of SM-130686 on GH release in pentobarbital-anesthetized rats was studied. After treatment with 10 mg/kg SM-130686, plasma GH concentrations measured by radioimmunoassay significantly increased, reaching a peak at 20-45 min, and remained above baseline during the experimental period (60 min). The anabolic effect of repetitive SM-130686 administration was studied in rats. Rats received 10 mg/kg SM-130686 orally twice a day and were weighed every day for 9 days. At day 9 there was a significant increase in both the body weight and the fat free mass (19.5+/-2.1 and 18.1+/-7.5 g respectively). Serum IGF-I concentration was also significantly elevated 6 h after the last dose of SM-130686. An endogenous GHS ligand for the GHS receptor has recently been identified from stomach extract and designated as ghrelin. The GH-releasing activity in vitro relative to ghrelin (100%) was about 52% for SM-130686. It is likely that SM-130686 is a partial agonist for the GHS receptor. In summary, we describe here an orally active GHS, SM-130686, which acts through the GHS receptor. Repetitive administration of SM-130686 to rats, similar to repetitive administration of GH, significantly increased the fat free mass by an amount almost equal to the gain in body weight.
SM - 130686是一种氧化吲哚衍生物,是一种新型的口服活性生长激素促分泌素(GHS),其结构与先前报道的GHS如MK - 677、NN703和六肽促生长素不同。SM - 130686以剂量依赖的方式刺激培养的大鼠垂体细胞释放生长激素。在浓度为6.3±3.4 nM时观察到半数最大刺激。GHS拮抗剂可抑制SM - 130686诱导的生长激素释放,但生长激素释放激素拮抗剂则无此作用。SM - 130686剂量依赖性地抑制放射性标记配体(35)S - MK - 677与人生长激素促分泌素受体1a的结合(IC50 = 1.2 nM)。这表明SM - 130686通过生长激素促分泌素受体刺激生长激素释放。研究了单次口服SM - 130686对戊巴比妥麻醉大鼠生长激素释放的影响。用10 mg/kg SM - 130686处理后,通过放射免疫测定法测得的血浆生长激素浓度显著升高,在20 - 45分钟达到峰值,并在实验期(60分钟)内保持高于基线水平。研究了重复给予SM - 130686对大鼠的合成代谢作用。大鼠每天口服两次10 mg/kg SM - 130686,连续9天每天称重。在第9天,体重和去脂体重均显著增加(分别为19.5±2.1和18.1±7.5 g)。在最后一剂SM - 130686后6小时,血清胰岛素样生长因子 - I浓度也显著升高。最近从胃提取物中鉴定出一种生长激素促分泌素受体的内源性GHS配体,并将其命名为胃饥饿素。相对于胃饥饿素(100%),SM - 130686在体外的生长激素释放活性约为52%。SM - 130686可能是生长激素促分泌素受体的部分激动剂。总之,我们在此描述了一种口服活性GHS,即SM - 130686,它通过生长激素促分泌素受体发挥作用。对大鼠重复给予SM - 130686,与重复给予生长激素类似,显著增加了去脂体重,增加量几乎与体重增加量相等。